Cytomegalovirus retinitis is the major cause of blindness in AIDS patients. Although we have previously shown that DHPG is effective in treating this infection, the disease relapses without continued maintenance. Maintenance therapy requires intravenous infusion and is associated with marrow toxicity. A multi-center randomized trial is currently being planned to evaluate the use of this drug.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Intramural Research (Z01)
Project #
1Z01EY000218-03
Application #
3941663
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code